

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Pancreatic cancer	CXC chemokine receptor 2 (CXCR2; IL8RB)	A study in mice suggests antagonizing CXCR2 could help treat pancreatic ductal adenocarcinoma. In a mouse model of the disease, a Cxcr2 inhibitor plus the chemotherapeutic gemcitabine decreased tumor growth compared with either drug alone. Next steps include optimizing the dosing of gemcitabine and a CXCR2 inhibitor. At least four companies have CXCR2 antagonists in clinical trials for pulmonary or transplant indications.	Unpatented; licensing status not applicable	Ijichi, H. <i>et al. J. Clin. Invest.</i> ; published online Sept. 19, 2011; doi:10.1172/JCI42754 <b>Contact:</b> Hideaki Ijichi, The University of Tokyo, Tokyo, Japan e-mail: <a href="mailto:hideijichi-gi@umin.ac.jp">hideijichi-gi@umin.ac.jp</a>
<p><b>SciBX 4(40); doi:10.1038/scibx.2011.1114</b>  <b>Published online Oct. 13, 2011</b></p>				